XML 47 R33.htm IDEA: XBRL DOCUMENT v3.23.3
Revenue recognition and accounts receivable (Tables)
9 Months Ended
Sep. 30, 2023
Revenue Recognition And Accounts Receivable [Abstract]  
Schedule of Net Sales by Major Product Category by Reporting Segment

The table below presents net sales by major product category by reporting segment:

 

 

 

Three Months Ended September 30,

 

(Unaudited, U.S. Dollars, in thousands)

 

2023

 

 

2022

 

 

Change

 

Bone Growth Therapies

 

$

53,359

 

 

$

46,531

 

 

 

14.7

%

Spinal Implants, Biologics, and Enabling Technologies

 

 

100,993

 

 

 

39,655

 

 

 

154.7

%

Global Spine

 

 

154,352

 

 

 

86,186

 

 

 

79.1

%

Global Orthopedics

 

 

29,654

 

 

 

27,810

 

 

 

6.6

%

Net sales

 

$

184,006

 

 

$

113,996

 

 

 

61.4

%

 

 

 

Nine Months Ended September 30,

 

(Unaudited, U.S. Dollars, in thousands)

 

2023

 

 

2022

 

 

Change

 

Bone Growth Therapies

 

$

153,735

 

 

$

136,244

 

 

 

12.8

%

Spinal Implants, Biologics, and Enabling Technologies

 

 

307,799

 

 

 

123,379

 

 

 

149.5

%

Global Spine

 

 

461,534

 

 

 

259,623

 

 

 

77.8

%

Global Orthopedics

 

 

84,692

 

 

 

78,861

 

 

 

7.4

%

Net sales

 

$

546,226

 

 

$

338,484

 

 

 

61.4

%

Schedule of Components Net Sales

The table below presents product sales and marketing service fees, which are both components of net sales:

 

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

(Unaudited, U.S. Dollars, in thousands)

 

2023

 

 

2022

 

 

2023

 

 

2022

 

Product sales

 

$

170,666

 

 

$

100,485

 

 

$

506,992

 

 

$

296,652

 

Marketing service fees

 

 

13,340

 

 

 

13,511

 

 

 

39,234

 

 

 

41,832

 

Net sales

 

$

184,006

 

 

$

113,996

 

 

$

546,226

 

 

$

338,484

 

Allowances for Expected Credit Losses

The following table provides a detail of changes in the Company’s allowance for expected credit losses for the three and nine months ended September 30, 2023 and 2022:

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

(Unaudited, U.S. Dollars, in thousands)

 

2023

 

 

2022

 

 

2023

 

 

2022

 

Allowance for expected credit losses beginning balance

 

$

7,015

 

 

$

5,589

 

 

$

6,419

 

 

$

4,944

 

Addition resulting from the Merger with SeaSpine

 

 

 

 

 

 

 

 

137

 

 

 

 

Current period provision for expected credit losses

 

 

415

 

 

 

574

 

 

 

905

 

 

 

1,713

 

Write-offs charged against the allowance and other

 

 

(214

)

 

 

10

 

 

 

(334

)

 

 

(236

)

Effect of changes in foreign exchange rates

 

 

(126

)

 

 

(225

)

 

 

(37

)

 

 

(473

)

Allowance for expected credit losses ending balance

 

$

7,090

 

 

$

5,948

 

 

$

7,090

 

 

$

5,948